TELA
TELA Bio, Inc. NASDAQ Listed Nov 8, 2019$1.10
Mkt Cap $49.2M
52w Low $0.50
35.3% of range
52w High $2.20
50d MA $0.75
200d MA $1.18
P/E (TTM)
-1.2x
EV/EBITDA
-1.8x
P/B
7.3x
Debt/Equity
8.8x
ROE
-615.1%
P/FCF
-1.9x
RSI (14)
—
ATR (14)
—
Beta
0.99
50d MA
$0.75
200d MA
$1.18
Avg Volume
223.6K
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
1 Great Valley Parkway · Malvern, PA 19355 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.18 | -0.16 | +11.1% | 0.69 | -2.9% | +8.1% | -2.9% | -18.1% | -10.2% | -17.6% | — |
| Nov 13, 2025 | AMC | -0.17 | -0.19 | -11.8% | 1.11 | -5.4% | -10.0% | +2.7% | +6.3% | -2.7% | -4.5% | — |
| Aug 11, 2025 | AMC | -0.18 | -0.22 | -22.2% | 1.86 | -4.8% | -14.0% | -21.0% | -14.0% | -15.1% | -8.6% | — |
| May 8, 2025 | AMC | -0.21 | -0.25 | -19.0% | 0.99 | +1.0% | +9.0% | +2.0% | -1.1% | -0.1% | -1.1% | — |
| Mar 20, 2025 | AMC | -0.24 | -0.23 | +4.2% | 2.34 | -18.8% | -37.2% | -40.2% | -47.0% | -44.9% | -41.5% | — |
| Nov 7, 2024 | AMC | -0.37 | -0.42 | -13.5% | 2.99 | -2.7% | +3.0% | -1.7% | +4.0% | +2.3% | +1.7% | — |
| Aug 12, 2024 | AMC | -0.45 | -0.51 | -13.3% | 4.01 | -20.2% | -22.9% | -24.4% | -23.4% | -22.4% | -23.4% | — |
| May 9, 2024 | AMC | -0.48 | -0.23 | +52.1% | 4.94 | +9.9% | +16.8% | +17.4% | +17.8% | +21.1% | +28.7% | — |
| Mar 21, 2024 | AMC | -0.44 | -0.53 | -20.5% | 5.35 | +4.5% | +7.1% | +1.7% | +3.9% | +4.9% | +6.0% | — |
| Nov 9, 2023 | AMC | -0.52 | -0.45 | +13.5% | 5.73 | -12.7% | -19.4% | -21.5% | -20.8% | -16.2% | -17.1% | — |
| Aug 9, 2023 | AMC | -0.58 | -0.46 | +20.7% | 9.07 | -2.9% | -3.3% | -1.0% | +0.3% | -0.3% | -0.8% | — |
| May 11, 2023 | AMC | -0.51 | -0.63 | -23.5% | 9.96 | -1.8% | -3.7% | -4.8% | -4.9% | -3.0% | -3.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | Citizens | Maintains | Market Outperform → Market Outperform | — | $0.75 | $0.73 | -2.7% | -10.2% | -24.3% | -16.9% | -23.8% | -19.9% |
| Mar 25 | Piper Sandler | Maintains | Neutral → Neutral | — | $0.76 | $0.76 | -0.0% | -9.4% | -2.0% | -12.0% | -25.8% | -18.6% |
| Mar 25 | Lake Street | Maintains | Buy → Buy | — | $0.76 | $0.76 | -0.0% | -9.4% | -2.0% | -12.0% | -25.8% | -18.6% |
| Mar 25 | Canaccord Genuity | Maintains | Buy → Buy | — | $0.76 | $0.76 | -0.0% | -9.4% | -2.0% | -12.0% | -25.8% | -18.6% |
| Dec 1 | Lake Street | Maintains | Buy → Buy | — | $1.15 | $1.16 | +0.9% | -1.7% | -0.9% | +0.0% | -0.9% | +0.0% |
| Nov 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.14 | $1.23 | +7.9% | +3.5% | -5.3% | -7.0% | +2.6% | +0.0% |
| Nov 14 | Piper Sandler | Maintains | Neutral → Neutral | — | $1.11 | $1.05 | -5.4% | -10.0% | +2.7% | +6.3% | -2.7% | -4.5% |
| Nov 14 | Citizens | Maintains | Market Outperform → Market Outperform | — | $1.11 | $1.05 | -5.4% | -10.0% | +2.7% | +6.3% | -2.7% | -4.5% |
| Mar 21 | Piper Sandler | Downgrade | Overweight → Neutral | — | $2.34 | $1.90 | -18.8% | -37.2% | -40.2% | -47.0% | -44.9% | -41.5% |
| Mar 21 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.34 | $1.90 | -18.8% | -37.2% | -40.2% | -47.0% | -44.9% | -41.5% |
| Mar 21 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $2.34 | $1.90 | -18.8% | -37.2% | -40.2% | -47.0% | -44.9% | -41.5% |
| Nov 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.99 | $2.91 | -2.7% | +3.0% | -1.7% | +4.0% | +2.3% | +1.7% |
| Oct 4 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.52 | $2.53 | +0.4% | +7.1% | +4.0% | -0.8% | -3.6% | -5.6% |
| Aug 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.01 | $3.20 | -20.2% | -22.9% | -24.4% | -23.4% | -22.4% | -23.4% |
| Aug 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.01 | $3.20 | -20.2% | -22.9% | -24.4% | -23.4% | -22.4% | -23.4% |
| Aug 13 | Lake Street | Maintains | Buy → Buy | — | $4.01 | $3.20 | -20.2% | -22.9% | -24.4% | -23.4% | -22.4% | -23.4% |
| Aug 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.01 | $3.20 | -20.2% | -22.9% | -24.4% | -23.4% | -22.4% | -23.4% |
| Jul 25 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.58 | $4.60 | +0.4% | -1.7% | +0.4% | -0.7% | -3.3% | -2.8% |
| May 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.94 | $5.43 | +9.9% | +16.8% | +17.4% | +17.8% | +21.1% | +28.7% |
| Mar 22 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.35 | $5.59 | +4.5% | +7.1% | +1.7% | +3.9% | +4.9% | +6.0% |
| Mar 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.35 | $5.59 | +4.5% | +7.1% | +1.7% | +3.9% | +4.9% | +6.0% |
| Dec 27 | Lake Street | Maintains | Buy → Buy | — | $6.52 | $6.57 | +0.8% | -3.5% | -3.2% | +1.5% | +1.5% | +1.4% |
| Nov 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $5.73 | $5.00 | -12.7% | -19.4% | -21.5% | -20.8% | -16.2% | -17.1% |
| Mar 28 | Canaccord Genuity | Maintains | Buy → Buy | — | $10.49 | $10.35 | -1.3% | +3.3% | +5.1% | +7.1% | +1.4% | +4.8% |
| Mar 22 | JMP Securities | Maintains | Market Outperform → Outperform | — | $10.49 | $10.50 | +0.1% | -5.9% | -4.6% | -4.2% | +0.0% | +3.3% |
| Nov 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.50 | $7.01 | +7.8% | +24.6% | +24.8% | +21.8% | +24.6% | +23.1% |
| Nov 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.50 | $7.01 | +7.8% | +24.6% | +24.8% | +21.8% | +24.6% | +23.1% |
| Aug 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $13.13 | $13.79 | +5.0% | +5.9% | +0.2% | +4.6% | +3.6% | +2.9% |
| Jul 9 | Jefferies | Maintains | Buy → Buy | — | $13.21 | $13.90 | +5.2% | -1.2% | +2.3% | +0.1% | +4.5% | +7.4% |
| Jun 18 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $19.91 | $20.00 | +0.5% | +8.8% | +13.6% | +5.0% | +6.9% | -0.1% |
| Jun 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $16.82 | $17.49 | +4.0% | -1.8% | +1.1% | +0.3% | +8.7% | +14.0% |
| May 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $11.01 | $11.86 | +7.7% | +8.7% | +6.5% | +7.4% | +15.8% | +29.4% |
| Dec 3 | JMP Securities | Maintains | Market Outperform → Outperform | — | $12.31 | $12.65 | +2.8% | +5.3% | +6.7% | -1.9% | +0.5% | -1.3% |
| Dec 3 | Jefferies | Maintains | Buy → Buy | — | $12.31 | $12.65 | +2.8% | +5.3% | +6.7% | -1.9% | +0.5% | -1.3% |
| Dec 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $12.31 | $12.65 | +2.8% | +5.3% | +6.7% | -1.9% | +0.5% | -1.3% |
| Dec 3 | PiperJaffray | Maintains | Overweight → Overweight | — | $12.31 | $12.65 | +2.8% | +5.3% | +6.7% | -1.9% | +0.5% | -1.3% |
No insider trades available.
8-K · 5.02
!!! Very High
TELA Bio, Inc. -- 8-K 5.02: Executive Change
TELA Bio appointed Doug Evan and Joseph Capper as independent directors, strengthening board governance and potentially signaling confidence in the company's strategic direction.
Apr 30
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This 8-K filing contains minimal substantive disclosure—just procedural exhibit references—suggesting Tela either made routine announcements or the company chose minimal required disclosure, warranting scrutiny of actual exhibits for material news.
Mar 24
8-K
Unknown — 8-K Filing
TELA's stock price has fallen below Nasdaq's $1 minimum bid requirement, threatening its listing unless the company successfully appeals or reverses the decline within 180 days.
Mar 20
Data updated apr 27, 2026 4:24am
· Source: massive.com